enGene Therapeutics (FRA:S0N0) Beneish M-Score: 0.00 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S0N0 enGene Therapeutics Inc FRA:S0N0
19 GF Score
Price €1.43
! 1 Warning Sign
View Full Analysis

What is enGene Therapeutics Beneish M-Score?

enGene Therapeutics FRA:S0N0 -2.05% 19 Beneish M-Score is 0.00 as of Aug. 18, 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 820 Biotechnology companies, enGene Therapeutics ranks worse than 121951.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for enGene Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 6 years, the highest Beneish M-Score of enGene Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.

enGene Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for enGene Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Therapeutics Beneish M-Score Chart

enGene Therapeutics Annual Data
Trend Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

enGene Therapeutics Quarterly Data
Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:S0N0 vs VTVT, GUTS, VXRT: Beneish M-Score Comparison

For the Biotechnology subindustry, enGene Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

enGene Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where enGene Therapeutics's Beneish M-Score falls into.


FRA:S0N0
19GF Score
enGene Therapeutics Inc FRA:S0N0
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enGene Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of enGene Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Apr26) TTM:Last Year (Apr25) TTM:
Total Receivables was €0.70 Mil.
Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Total Current Assets was €230.85 Mil.
Total Assets was €262.93 Mil.
Property, Plant and Equipment(Net PPE) was €8.07 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.57 Mil.
Selling, General, & Admin. Expense(SGA) was €30.29 Mil.
Total Current Liabilities was €18.37 Mil.
Long-Term Debt & Capital Lease Obligation was €26.40 Mil.
Net Income was -25.844 + -25.319 + -32.539 + -24.845 = €-108.55 Mil.
Non Operating Income was -0.151 + -0.489 + -0.104 + -0.24 = €-0.98 Mil.
Cash Flow from Operations was -26.076 + -24.596 + -21.442 + -21.968 = €-94.08 Mil.
 Total Receivables was €0.47 Mil.
Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Total Current Assets was €202.90 Mil.
Total Assets was €237.32 Mil.
Property, Plant and Equipment(Net PPE) was €2.84 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.35 Mil.
Selling, General, & Admin. Expense(SGA) was €25.68 Mil.
Total Current Liabilities was €16.02 Mil.
Long-Term Debt & Capital Lease Obligation was €19.01 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.703 / 0) / (0.474 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (230.85 + 8.071) / 262.933) / (1 - (202.897 + 2.842) / 237.319)
=0.091324 / 0.13307
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.345 / (0.345 + 2.842)) / (0.573 / (0.573 + 8.071))
=0.108252 / 0.066289
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(30.29 / 0) / (25.678 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((26.395 + 18.37) / 262.933) / ((19.01 + 16.021) / 237.319)
=0.170252 / 0.147611
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-108.547 - -0.984 - -94.082) / 262.933
=-0.051272

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
enGene Therapeutics (FRA:S0N0) has a Beneish M-Score of 0.00 as of Aug. 18, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #999999 out of 820 companies in the Biotechnology industry.
Is enGene Therapeutics' Beneish M-Score too high?
enGene Therapeutics' current Beneish M-Score is 0.00. Based on the distribution chart, enGene Therapeutics ranks #999999 out of 820 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Beneish M-Score compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #999999 out of 820 companies for Beneish M-Score. This places enGene Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Beneish M-Score is 0.00 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enGene Therapeutics Business Description

Other Exchanges ENGN:USA
Address 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score

Get the complete analysis for FRA:S0N0

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.43
Price